Asset
INFIGRATINIB
BRIDGEBIO PHARMA INC. COMMON STOCK
Revenue
No revenue reported in loaded filings.
Clinical trials (8)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT02150967 | phase2 | terminated | 2014-07-23 | 2021-03-01 | QED Therapeutics, a BridgeBio company | A Phase II, Single Arm Study of BGJ398 in Patients With Advanced Cholangiocarcinoma |
| NCT06164951 | phase3 | completed | 2023-11-10 | 2025-12-18 | QED Therapeutics, a BridgeBio company | A Study to Evaluate the Efficacy and Safety of Infigratinib in Children and Adolescents With Achondroplasia |
| NCT06873035 | phase2_3 | enrolling_by_invitation | 2025-04-22 | 2027-01-01 | QED Therapeutics, a BridgeBio company | An Interventional Study of Infigratinib in Children With Hypochondroplasia |
| NCT05145010 | phase2 | enrolling_by_invitation | 2021-12-06 | 2031-12-01 | QED Therapeutics, a BridgeBio company | Extension Study of Infigratinib in Children With Achondroplasia (ACH) |
| NCT07393373 | phase2 | enrolling_by_invitation | 2026-04-23 | 2036-05-31 | QED Therapeutics, a BridgeBio company | Open-Label, Long-Term, Extension Study of Infigratinib in Children With Hypochondroplasia |
FDA applications (0)
This company has no applications containing this asset.